New preclinical data supports the positive effects of Liminal Biosciences’s lead candidate, PBI-4050, in reducing pulmonary hypertension and the abnormal enlargement of the heart’s right ventricle muscle. The company presented its latest data on two posters at the American Heart Association 2019 conference, held recently in Philadelphia. The…
Research & DevelopmentTreatment with the approved anti-cancer medication sorafenib reversed pulmonary arterial hypertension (PAH) and cardiopulmonary remodeling (CPR) in a rat model, according to a new study. The findings suggest that a low-dose therapy with this compound may be successful in PAH treatment, the Japanese research team suggests.
ProMetic Life Sciences recently presented positive preclinical data on its fibrosis-targeting lead candidate, PBI-4050, showing that the drug effectively reduces pulmonary hypertension and right ventricular hypertrophy. The company also presented positive effects of PBI-4050 on cardiovascular biomarkers in patients with metabolic syndrome and type 2 diabetes. The data…
Get regular updates to your inbox.